Initial studies on the recently developed recombinant THPOR agonists (Eltrombopag, first-generation Romiplostim, and first- and second-generation Avatrombopag) have shown these agents to be beneficial in CLD and HCC patients, especially in improving platelet counts. Here, MPL is linked to hepatocellular carcinoma.